Terms: = Cervical cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Clinical Outcome
3 results:
1. Variation of pd-l1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy.
Liang Y; Yu M; Zhou C; Zhu X
Diagn Pathol; 2020 Jun; 15(1):67. PubMed ID: 32493336
[TBL] [Abstract] [Full Text] [Related]
2. Adenocarcinoma of the uterine cervix: Pathologic features, treatment options, clinical outcome and prognostic variables.
Gadducci A; Guerrieri ME; Cosio S
Crit Rev Oncol Hematol; 2019 Mar; 135():103-114. PubMed ID: 30819439
[TBL] [Abstract] [Full Text] [Related]
3. Immune Checkpoint Inhibitors in Gynecological cancers: Update of Literature and Perspectives of clinical Research.
Gadducci A; Guerrieri ME
Anticancer Res; 2017 Nov; 37(11):5955-5965. PubMed ID: 29061774
[TBL] [Abstract] [Full Text] [Related]
